VCP
VKTX icon

Verus Capital Partners’s Viking Therapeutics VKTX Stock Holding History

Verus Capital Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,700
Closed -$221K – 374
2024
Q1 		$221K Buy
+2,700
New +$120K 0.02% 320
2020
Q1 		$15K Sell
3,100
-200
-6% -$1.23K ﹤0.01% 896
2019
Q4 		$26K Buy
+3,300
New +$24.1K 0.01% 799

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Verus Capital Partners's VKTX Position: Q2 2024 in Review

Verus Capital Partners sold out of Viking Therapeutics (VKTX) in Q2 2024, closing a stake of 2,700 shares — an estimated $221K sold.

Verus Capital Partners first reported a position in VKTX in Q4 2019 and held it in 3 quarters. The position peaked at $221K in Q1 2024. 387 funds tracked by Wall St. Rank hold VKTX as of Q2 2024.

  • Verus Capital Partners reported no remaining Viking Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Verus Capital Partners sold 2,700 Viking Therapeutics shares in Q2 2024, an estimated $221K.
  • Verus Capital Partners first reported a position in Viking Therapeutics in Q4 2019 and held it in 3 quarters.
  • Verus Capital Partners's Viking Therapeutics position peaked at $221K in Q1 2024.
  • 387 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2024.

Based on Verus Capital Partners's 13F filing for Q2 2024, filed 1 Aug 2024.